It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDAP’s FA Score shows that 0 FA rating(s) are green whileYI’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDAP’s TA Score shows that 6 TA indicator(s) are bullish while YI’s TA Score has 6 bullish TA indicator(s).
EDAP (@Medical Distributors) experienced а +11.87% price change this week, while YI (@Medical Distributors) price change was +14.54% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was -0.50%. For the same industry, the average monthly price growth was -0.93%, and the average quarterly price growth was +1.71%.
EDAP is expected to report earnings on May 14, 2025.
YI is expected to report earnings on Mar 13, 2025.
Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
EDAP | YI | EDAP / YI | |
Capitalization | 282M | 97.4M | 290% |
EBITDA | -18.39M | -238.88M | 8% |
Gain YTD | 25.792 | 28.331 | 91% |
P/E Ratio | 100.00 | N/A | - |
Revenue | 60.4M | 14.7B | 0% |
Total Cash | 43.5M | 699M | 6% |
Total Debt | 8.42M | 398M | 2% |
EDAP | YI | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 52 | 37 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
YI's Valuation (73) in the Drugstore Chains industry is in the same range as EDAP (98) in the Biotechnology industry. This means that YI’s stock grew similarly to EDAP’s over the last 12 months.
YI's Profit vs Risk Rating (100) in the Drugstore Chains industry is in the same range as EDAP (100) in the Biotechnology industry. This means that YI’s stock grew similarly to EDAP’s over the last 12 months.
EDAP's SMR Rating (97) in the Biotechnology industry is in the same range as YI (100) in the Drugstore Chains industry. This means that EDAP’s stock grew similarly to YI’s over the last 12 months.
YI's Price Growth Rating (37) in the Drugstore Chains industry is in the same range as EDAP (52) in the Biotechnology industry. This means that YI’s stock grew similarly to EDAP’s over the last 12 months.
YI's P/E Growth Rating (100) in the Drugstore Chains industry is in the same range as EDAP (100) in the Biotechnology industry. This means that YI’s stock grew similarly to EDAP’s over the last 12 months.
EDAP | YI | |
---|---|---|
RSI ODDS (%) | 6 days ago80% | 6 days ago90% |
Stochastic ODDS (%) | 6 days ago84% | 6 days ago90% |
Momentum ODDS (%) | 6 days ago79% | 6 days ago76% |
MACD ODDS (%) | 6 days ago86% | 6 days ago74% |
TrendWeek ODDS (%) | 6 days ago75% | 6 days ago76% |
TrendMonth ODDS (%) | 6 days ago80% | 6 days ago74% |
Advances ODDS (%) | 21 days ago76% | 6 days ago77% |
Declines ODDS (%) | about 1 month ago83% | 19 days ago86% |
BollingerBands ODDS (%) | 6 days ago75% | 6 days ago90% |
Aroon ODDS (%) | 6 days ago84% | 6 days ago78% |
A.I.dvisor tells us that EDAP and AHG have been poorly correlated (+10% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EDAP and AHG's prices will move in lockstep.
Ticker / NAME | Correlation To EDAP | 1D Price Change % | ||
---|---|---|---|---|
EDAP | 100% | -2.80% | ||
AHG - EDAP | 10% Poorly correlated | -2.31% | ||
COR - EDAP | 9% Poorly correlated | -0.49% | ||
ZYXI - EDAP | 7% Poorly correlated | +1.59% | ||
YI - EDAP | 5% Poorly correlated | +4.51% | ||
COSM - EDAP | 3% Poorly correlated | -0.23% | ||
More |
A.I.dvisor tells us that YI and SNYR have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that YI and SNYR's prices will move in lockstep.